86945-27-9

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-Benzyl-4-cyanomethyl-piperidine-4-carbonitrile is used as a core intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique molecular structure and synthetic properties contribute to the development of drugs with potential therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Benzyl-4-cyanomethyl-piperidine-4-carbonitrile is utilized as a key building block for the creation of complex organic molecules. Its versatility and reactivity in chemical reactions make it an essential component in the synthesis of a wide range of organic compounds.
Used in Medicinal Chemistry:
1-Benzyl-4-cyanomethyl-piperidine-4-carbonitrile is employed in medicinal chemistry as a starting material for the design and synthesis of new drug candidates. Its structural features and synthetic capabilities enable the development of innovative therapeutic agents with improved pharmacological properties and efficacy.
Used in Drug Discovery:
In the drug discovery process, 1-Benzyl-4-cyanomethyl-piperidine-4-carbonitrile serves as a valuable chemical probe for the identification and optimization of potential drug candidates. Its unique structural elements and synthetic accessibility facilitate the exploration of novel chemical space and the discovery of new therapeutic agents with promising biological activities.

InChI:InChI=1/C15H17N3/c16-9-6-15(13-17)7-10-18(11-8-15)12-14-4-2-1-3-5-14/h1-5H,6-8,10-12H2

Upstream product

• 1463-52-1 ethyl 2-(1-benzylpiperidin-4-ylidene)-2-cyanoacetate 
• 151-50-8 potassium cyanide 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1187036-97-0 benzyl 2,3,4-tri-O-benzyl-6-O-(N-(2-ethyl-2,8-diazaspiro[4,5]decane-1,3-dione)aminocarbonyl)-β-D-glucopyranoside 
• 1463-47-4 8-benzyl-2-ethyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 2079-24-5 2-ethyl-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 941691-23-2 2-(4-methoxy-benzyl)-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 40118-06-7 2-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-ethanol 
• 176-69-2 2-oxa-8-azaspiro[4.5]decane 
• 64097-82-1 8-benzyl-2-methyl-2,8-diaza-spiro[4.5]decane 
• 1061873-16-2 2-methyl-2,8-diazaspiro[4.5]decane 
• 236406-38-5 1,1-dimethylethyl 4-(2-hydroxyethyl)-4-(hydroxymethyl)-1-piperidinecarboxylate 
• 929301-95-1 C₁₅H₂₉NO₈S₂ 
• 1463-48-5 8-benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione 

Relevant academic research and scientific papers

SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF

The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF

The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.

Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists

In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane scaffold as a template. We describe here our investigation of a variety of templates including spiropiperidinyl-γ -lactams, spiropiperidinylimide, spiropiperidinylureas, and spiropiperidinylhydantoins. With the appropriate acidic and basic pharmacophores in place, each template yielded analogues with potent GPIIb-IIIa inhibitory activity. One of the compounds, 59 (CT50787), was also used to demonstrate for the first time the use of a pharmacological agent which is αIIbβ3 specific to display biological activity in a lower species such as mouse and to extend bleeding times. Evaluation of the pharmacokinetic properties of selected compounds from each series in rat, dog, and cynomolgus monkey has led to the identification of 22 (CT51464), a double prodrug, with excellent pharmacokinetic properties. It exhibited good pharmacokinetic profile across species (F% = 33 (Cyno), 73 (dog), 22 (rat); t1/2β = 14. 2 h (Cyno), 8.97 h (dog), 1.81 h (rat)). The biologically active form, 23 (CT50728), displayed inhibition of platelet aggregation in platelet rich plasma (PRP) with an IC50 value of 53 nM in citrate buffer, 110 nM in PPACK anticoagulated PRP, and 4 nM in solid-phase GPIIb-IIIa competition binding assay (ELISA). Both 23 and 22 were stable in human liver microsomes, did not inhibit the P450 3A4 isozyme, and had low protein binding (18.22% for 23) and a desirable log P (0.45 ± 0.06 for 22, and -0.91 ± 0.32 for 23). It is predicted that the high oral bioavailability for these compounds in multiple species should translate into lower intra- and intersubject variability in man. The long plasma half-life of the lead is consistent with once or twice daily administration for chronic therapy. Analogue 22 (CT51464) thus appears to be a promising oral GPIIb-IIIa inhibitor with significantly improved pharmacokinetic properties over the previously described clinical candidates and may be found useful in the treatment of arterial occlusive disorders.

SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES

The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics.